Next™ BriefBiosecurity and the Future of Pathogen Surveillance
Buy Now
Meticulous Next™HealthcareNov 2026104 ppMRN-1371

Pathogen surveillance Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

Brief ID: MRN-1371Format: PDF + Summary DeckDelivery: InstantHorizon: 10-yr horizonSignal: High-impact
Buy Now · $950
Adoption maturity (indexed)
Mainstream inflection: ~2031
Horizon: 2026–2036 · Signal: High-impact
10 yrs
Forward horizon
~2031
Mainstream inflection
High impact
Signal strength

What This Brief Covers

This Meticulous Next™ brief examines pathogen surveillance, the use of wastewater, traveler-based and clinical genomic programmes to detect outbreaks before they spread. It tests how fast pathogen-agnostic sequencing and sustained public funding turn pilot programmes into standard public health infrastructure, and which participants capture value among sequencing and diagnostics suppliers, testing laboratories, research institutes and funders.

Sampling has reached national scale in the United States. The Traveler-Based Genomic Surveillance programme of the US Centers for Disease Control and Prevention has enrolled more than 1 million travelers and analysed more than 2,600 wastewater samples from aircraft, with Ginkgo Biosecurity and XWELL among its sequencing partners, and in 2023 it identified novel H3N2 influenza subclades several days before domestic clinical laboratories reported them. The conclusion is that sampling at points of entry shortens detection lead time, which helps laboratories update assays and plan reagents before a variant spreads in the community.

Untargeted sequencing is widening what can be detected. A preprint posted on medRxiv in March 2026 from the Coalition for Agnostic Sequencing of Pathogens from Environmental Reservoirs described 1,206 wastewater samples collected from 27 sites in nine states between December 2023 and December 2025, serving about 13 million people, with about 1 billion read pairs per sample. The data detected avian influenza H5N1 during the early dairy cattle outbreaks, West Nile virus and measles, and the group accounts for 66% of untargeted wastewater sequencing data in the NCBI Sequence Read Archive. The conclusion is that pathogen-agnostic sequencing covers threats that targeted tests miss, and its data volume favours suppliers of sequencing and analysis.

Low- and middle-income countries depend on grant funding. The International Pathogen Surveillance Network, hosted by the WHO Hub for Pandemic and Epidemic Intelligence in Berlin, awarded a USD 2 million first round to 10 projects in November 2024 and opened a USD 1.8 million second round in April 2026, funded by the Gates Foundation, the Rockefeller Foundation, Wellcome and the Institute of Philanthropy. The conclusion is that surveillance in these countries grows through small grants and pilots, and the scale of purchasing depends on whether governments take over the financing.

The brief treats pathogen surveillance as a high-impact signal with a ten year horizon to 2036. It identifies which applications, regions and operators scale first and what each means for suppliers, service providers, public health agencies and funders. It is a focused 104-page decision brief that presents an indicative trajectory rather than a segmented market model.

Brief Snapshot
ParameterDetails
Forward horizon2026–2036 (10 years)
Emerging forcePathogen surveillance: wastewater and genomic surveillance programmes for outbreak detection
Technology readinessNational traveler and wastewater programmes in operation in the United States; pathogen-agnostic sequencing at scale in research networks
Indicative market size & forecastThe pathogen surveillance market, covering sequencing, testing and informatics products and services bought for wastewater, traveler-based and clinical genomic surveillance programmes, is valued at USD 2.0–3.5 billion in 2026 and is projected to reach USD 8.09–14.16 billion by 2036, at a CAGR of 15%
Mainstream inflection~2031, when national metagenomic surveillance is standard public health infrastructure
Signal strengthMore than 1 million enrolled travelers, 1,206 sequenced wastewater samples from 27 sites and two grant rounds in low- and middle-income countries
Primary beneficiariesSequencing and diagnostics suppliers; surveillance service providers; public health agencies
Brief length / format104 pages · PDF + executive summary deck · instant delivery

Understanding the Technology

Pathogen surveillance monitors infectious agents in populations by testing wastewater, traveler samples and clinical specimens and sequencing the pathogens found.

Targeted tests look for named pathogens, and pathogen-agnostic metagenomic sequencing reads all genetic material in a sample and identifies what is present.

Analysis software compares sequences with public databases to flag new variants and report to public health agencies.

Uses are outbreak detection, variant tracking, avian influenza and zoonotic monitoring, and preparedness planning.

The limits are funding that follows outbreaks, sustained financing, data sharing and privacy concerns, and laboratory skills. The period turns on whether governments make surveillance a permanent budget line.

Market Outlook

The pathogen surveillance market, covering sequencing, testing and informatics products and services bought for wastewater, traveler-based and clinical genomic surveillance programmes, is valued at USD 2.0–3.5 billion in 2026 and is projected to reach USD 8.09–14.16 billion by 2036, at a CAGR of 15%.

The 2026 base rests on sequencing instruments and reagents, testing services and informatics bought by public health agencies, laboratories and research programmes. Growth then follows national wastewater and traveler programmes and pathogen-agnostic sequencing.

The forecast is sensitive to public health budgets, outbreak events and sequencing cost. Regionally, North America leads on programme scale, Europe on national strategies, and Asia-Pacific and Africa on grant-funded roll-out.

Scenarios

The base case assumes steady public budgets and no major new outbreak, giving the inflection in 2031. An accelerated case assumes a significant outbreak that triggers permanent funding, bringing the inflection to 2029 and lifting the 2036 value to the top of the range. A delayed case assumes budget cuts and privacy limits slow roll-out, holding growth at the bottom of the range.

Factors Behind Growth

Growth drivers

  • Outbreak preparedness funding.
  • Falling sequencing cost.
  • Wastewater and traveler programmes.
  • Avian influenza and emerging pathogen threats.

Enablers

  • Philanthropic and multilateral grants.
  • Public-private sequencing partnerships.
  • Open data platforms.
  • Laboratory capacity in low- and middle-income countries.

Restraints and barriers

  • Funding that follows outbreaks.
  • Sustained programme financing.
  • Data sharing and privacy concerns.
  • Laboratory and bioinformatics skills.

The Forces at Play

The direction of pathogen surveillance is set by the need for earlier outbreak detection, public health policy and funding, sequencing cost and data analysis, partnering among governments, philanthropy and industry, and data sharing and privacy.

Adoption Outlook

How the shift is likely to unfold across three time horizons.

Near term2026–2028
Grant funded roll-out

Grant rounds and wastewater networks widen coverage in low- and middle-income countries.

Mid term2028–2031
National metagenomic systems

Metagenomic sequencing becomes part of national surveillance systems.

Long term2031–2036
Standard public health infrastructure

Surveillance is standard public health infrastructure.

Latest Strategic Developments

DateDevelopmentTypeSignificance
Nov 2024The International Pathogen Surveillance Network announces USD 2 million in catalytic grants for 10 projects at its Global Partners Forum in BangkokFundingFunds genomic and wastewater surveillance in low- and middle-income countries
Feb 2026The CDC Traveler-Based Genomic Surveillance programme passes 1 million enrolled travelersProgrammeShows scale of traveler and aircraft wastewater sampling
Mar 2026The Coalition for Agnostic Sequencing of Pathogens from Environmental Reservoirs posts a preprint on 1,206 wastewater samples from 27 sitesResearchReleases the largest public untargeted wastewater sequencing dataset
Apr 2026The International Pathogen Surveillance Network opens a second round of catalytic grants of USD 1.8 millionFundingExtends grant funding for genomic and wastewater surveillance

Key Players & Competitive Landscape

The key participants in pathogen surveillance include Illumina, Inc., Oxford Nanopore Technologies plc, Pacific Biosciences of California, Inc., Thermo Fisher Scientific Inc., Danaher Corporation, QIAGEN N.V., bioMérieux S.A., Abbott Laboratories, F. Hoffmann-La Roche Ltd, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Seegene, Inc., Bruker Corporation, Revvity, Inc., Eurofins Scientific SE, Labcorp Holdings Inc., Quest Diagnostics Incorporated, Ginkgo Bioworks Holdings, Inc., Biobot Analytics, Inc., Verily Life Sciences LLC, XWELL, Inc., American University of Beirut, Institut Pasteur, Charles Stark Draper Laboratory, SecureBio, University of California San Diego, University of Miami, Gates Foundation, Rockefeller Foundation, Wellcome Trust, Institute of Philanthropy, United Nations Foundation, Pandemic Fund, U.S. Centers for Disease Control and Prevention, World Health Organization, European Centre for Disease Prevention and Control, UK Health Security Agency, Africa Centres for Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Illinois Department of Public Health, Chicago Department of Public Health, U.S. Food and Drug Administration and Association of Public Health Laboratories.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as pathogen surveillance matures.

Illumina, Oxford Nanopore Technologies, Pacific Biosciences and Thermo Fisher Scientific lead on sequencing, Ginkgo Bioworks, Biobot Analytics, Verily Life Sciences and XWELL lead on surveillance services, and the US Centers for Disease Control and Prevention and the World Health Organization lead on programmes and standards. Competitive intensity is moderate in 2026 and rises as programmes become permanent.

ArchetypeRepresentative playersPositionOutlook
Sequencing and diagnostics suppliersIllumina, Oxford Nanopore Technologies, Pacific Biosciences, Thermo Fisher Scientific, Danaher, QIAGEN, bioMérieux, Abbott, Roche, Becton Dickinson, Bio-Rad Laboratories, Seegene, Bruker, RevvitySequencers, assays and sample preparationSupply instruments, reagents and tests
Testing laboratories and surveillance service providersEurofins Scientific, Labcorp, Quest Diagnostics, Ginkgo Bioworks, Biobot Analytics, Verily Life Sciences, XWELLWastewater and traveler sampling and sequencing servicesRun sampling networks and sequencing
Research institutes and universitiesAmerican University of Beirut, Institut Pasteur, Charles Stark Draper Laboratory, SecureBio, University of California San Diego, University of MiamiMethods, data and pilotsDevelop methods and publish datasets
Funders and foundationsGates Foundation, Rockefeller Foundation, Wellcome Trust, Institute of Philanthropy, United Nations Foundation, Pandemic FundGrants and fund hostingFund programmes in low- and middle-income countries
Public health agencies and regulatorsU.S. Centers for Disease Control and Prevention, World Health Organization, European Centre for Disease Prevention and Control, UK Health Security Agency, Africa Centres for Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Illinois Department of Public Health, Chicago Department of Public Health, U.S. Food and Drug AdministrationProgrammes, guidance and clearancesRun programmes and set standards
Public health associationsAssociation of Public Health LaboratoriesLaboratory standards and trainingRepresent public health laboratories

Where value migrates.

In 2026 value sits with sequencing and sample collection suppliers, because programmes buy instruments, reagents and sampling services first. By 2031 it moves toward providers of pathogen-agnostic analysis and data platforms, because sequence volume makes analysis the constraint. By 2036 it settles in integrated national surveillance systems. Margins hold for suppliers with proprietary analysis and long service contracts and narrow for sellers of generic sequencing capacity.

Who Will Win — and Why

The archetypes best positioned to capture value as the shift matures.

Suppliers with sequencing and analysis platforms

Firms that provide sequencers, reagents and software used in public programmes.

Service providers with sampling networks

Firms that collect and sequence samples at many sites.

Agencies and funders with sustained programmes

Bodies with permanent budgets that set standards and data rules.

Regulatory Landscape

JurisdictionMilestoneIndicative timingEffect on adoption
WHO pandemic agreement and surveillance guidanceInternational agreement and guidance on pathogen sharing and surveillanceEmergingSet expectations for national surveillance and sample sharing
International Health RegulationsWHO rules on notification of public health eventsIn forceRequire reporting of events that surveillance detects
US public health surveillance programmesFederal programmes including traveler and wastewater surveillanceIn forceFund and define sampling and sequencing
EU and national surveillance strategiesEU and country plans for wastewater and genomic surveillanceEmergingSet coverage and data requirements in Europe
Data sharing and biosecurity rulesRules on sharing of pathogen sequences and sensitive dataEmergingAffect open data and privacy

Investment Signals

The signals converge on national scale sampling with fragile financing. More than 1 million enrolled travelers, 1,206 sequenced wastewater samples from 27 sites and two grant rounds support growth, while outbreak-driven funding, sustained financing and privacy concerns limit the pace.

Structural limits show where progress could slow: funding that follows outbreaks, sustained programme financing, data sharing and privacy concerns, and laboratory and bioinformatics skills. The brief therefore tracks four indicators: sites and samples sequenced, grant rounds, national programme budgets, and pathogen-agnostic detections.

Wastewater and traveler programmes first, then national metagenomic systems, then wider clinical and animal surveillance are the expected order of adoption.

Questions This Brief Answers

01What is pathogen surveillance, and why does it matter?
02What is the market size in 2026, and what is the forecast to 2036?
03What do the programme data indicate?
04What factors are driving growth, and what barriers remain?
05Which key participants are active, and which archetypes are positioned to win?
06What are the latest developments?
07How will funding and sequencing shape adoption between 2026 and 2036?
08What should suppliers, service providers and public health agencies do now?

Strategic Implications

  • Sequencing and diagnostics suppliers: build products for wastewater and metagenomic workflows and secure service contracts.
  • Service providers and laboratories: expand sampling networks and show detection lead time.
  • Public health agencies and funders: move programmes to permanent budgets and set data sharing rules.
  • Policy makers and regulators: clarify privacy rules and align international reporting.
  • Investors: treat sites and samples sequenced, grant rounds, programme budgets and pathogen-agnostic detections as the leading indicators.
Analyst Perspective

"Surveillance pays for itself only in the outbreak that does not happen. The market grows when governments fund it before that outbreak, not after."

Lead Foresight Analyst
Biotechnology & Life Sciences · Meticulous Next™

Table of Contents

Access & Licensing

A focused foresight brief, priced to circulate. Every option is delivered instantly and backed by analyst support.

Single Brief
$950
One named user
Full PDF brief
Executive summary deck
One named user
Free outlook update
★ Most Popular
Team License
$1,350
Up to 10 users
Access for 2–10 users
Internal sharing rights
30-minute analyst briefing
Enterprise
$2,150
Organization-wide
Organization-wide access
Unlimited users
Priority analyst access
Custom extracts
Included with
every brief
Analyst-reviewed foresightMulti-signal validationInstant deliveryFree outlook updates

Frequently Asked Questions

Search Market Intelligence

Search across reports, blogs, press releases, and industries